Degranulation assay to evaluate NK cell natural and antibody-dependent cell-mediated cytotoxicity against A549 tumor spheroids.


Journal

Methods in cell biology
ISSN: 0091-679X
Titre abrégé: Methods Cell Biol
Pays: United States
ID NLM: 0373334

Informations de publication

Date de publication:
2024
Historique:
medline: 12 10 2024
pubmed: 12 10 2024
entrez: 11 10 2024
Statut: ppublish

Résumé

Adoptive natural killer (NK) cell-based immunotherapy is a promising treatment approach in cancer that is showing notable efficacy against hematological malignancies. However, the success of NK cell immunotherapy in patients with solid tumors is limited due to several barriers, which include the immunosuppressive tumor microenvironment (TME), heterogeneity of tumor cells and poor NK cell infiltration into the tumor. Advances in 3D in vitro culture technologies have opened new avenues for the development of more physiological human cancer models that mimic important tumor features which are absent in traditional 2D studies and may be essential for the improvement of immunotherapies against solid tumors. Here, we describe a comprehensive protocol to generate tumor spheroids from the A549 lung carcinoma cell line, then establish co-cultures with NK cells to, ultimately, determine NK cell functional response with a degranulation assay, a surrogate of NK cell cytotoxicity against tumor spheroids. Additionally, we studied degranulation by stimulating NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) with cetuximab, an IgG1 monoclonal antibody used in cancer therapy. Likewise, other monoclonal antibodies or combination treatments could also be studied in this 3D co-culture system, providing very valuable information to define effective combinations of therapeutic agents able to generate NK cells with high cytotoxic potential that could lead to more successful adoptive NK cell-based therapies for the treatment of solid tumors.

Identifiants

pubmed: 39393889
pii: S0091-679X(24)00169-9
doi: 10.1016/bs.mcb.2024.06.003
pii:
doi:

Substances chimiques

Cetuximab PQX0D8J21J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

97-115

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Auteurs

Ainara Lopez-Pardo (A)

Immunopathology Group, Biobizkaia Health Research Institute, Barakaldo, Spain.

Ainhoa Amarilla-Irusta (A)

Immunopathology Group, Biobizkaia Health Research Institute, Barakaldo, Spain.

Víctor Sandá (V)

Immunopathology Group, Biobizkaia Health Research Institute, Barakaldo, Spain.

Mario Stan-Fontoba (M)

Immunopathology Group, Biobizkaia Health Research Institute, Barakaldo, Spain.

Francisco Borrego (F)

Immunopathology Group, Biobizkaia Health Research Institute, Barakaldo, Spain; Ikerbasque, Basque Foundation for Science, Bilbao, Spain.

Laura Amo (L)

Immunopathology Group, Biobizkaia Health Research Institute, Barakaldo, Spain; Ikerbasque, Basque Foundation for Science, Bilbao, Spain. Electronic address: laura.amoherrero@bio-bizkaia.eus.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH